Latest Product Launch News

ReNerve Limited has achieved a key milestone with its first sale and clinical use of a deep dermal tissue product in the US, broadening its surgical applications beyond nerve repair. This move complements its existing nerve repair portfolio and sets the stage for further product launches later this year.

Rhythm Biosciences has announced a $3.75 million placement to accelerate the commercial launch of its ColoSTAT® cancer detection test and expand its geneType™ product suite into key markets. The capital raise includes director participation and attaching options, pending shareholder approval.

GWA Group Limited reported modest revenue and earnings growth for FY2025, underpinned by strong Australian and UK markets, while announcing a $30 million on-market share buyback starting September 2025.

The a2 Milk Company reported a robust 21% rise in net profit for FY25, driven by strong growth in China and the USA, alongside a landmark full-year dividend declaration and major supply chain restructuring.

Microequities Asset Management Group reported a robust FY25 with significant profit growth and a new private credit product launch, signaling a strategic diversification and positive outlook for FY26.

Cochlear Limited reported a solid FY25 with 4% revenue growth and a 1% rise in underlying profit, underpinned by new product launches and expanding evidence linking implants to reduced dementia risk. The company’s FY26 outlook signals further gains as it advances market leadership and innovation.

Audeara Limited has secured a five-year licensing agreement with Eastech (Huizhou) Co., Ltd. to bring its advanced hearing technology to China’s booming medical device market, leveraging major e-commerce platforms for distribution.

CAR Group Limited has reported solid full-year FY25 results with revenue surpassing AUD 1.18 billion and adjusted NPAT rising to AUD 377 million, underpinned by global marketplace strength and strategic innovation. The company projects continued double-digit growth in FY26, driven by technology investments and market expansion.

AVITA Medical reported a 21% revenue increase in Q2 2025 driven by expanded sales and new product launches, yet continues to face net losses and liquidity challenges requiring loan covenant waivers.

FBR Limited has raised A$2 million through a share placement and purchase plan, complementing a $20 million subscription facility, to fund new robotic products, strategic partnerships, and debt repayment.

Block, Inc. reported a robust second quarter with 14% year-over-year gross profit growth, driven by strong performances from Cash App and Square. The company raised its full-year guidance, highlighting strategic expansions in peer-to-peer payments, AI tools, and bitcoin integration.

Vitrafy Life Sciences reported a 75% increase in FY25 sales driven by aquaculture and human health sectors, progressing its cryopreservation technology towards commercialisation in both unregulated and regulated markets in FY26.